Sanofi (NASDAQ:SNY) is one of the Best Affordable Stocks to Buy According to Analysts. On December 24, Sanofi (NASDAQ:SNY) ...

Unless such surprises materialize, analysts like Phipps see the Dynavax story as largely written, with most of the remaining upside and downside bounded by Sanofi’s $15.50 per share offer. Inhibikase ...

The post Dynavax Shares Jump On Vaccine News appeared first on Self Employed.

The Dow Jones Industrial Average ​rose ‌288.75 points, or 0.60%, to 48,731.16, ‍the S&P 500 gained 22.26 points, ⁠or 0.32%, to 6,932.05 and the Nasdaq Composite gained 51.46 points, or 0.22%, to ...

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

Dynavax soared by 38.19 percent on Wednesday to close at $15.38 apiece as investors took heart from news that it was set to ...

Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day. The S&P 500 index rose 22.26 ...

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas ...

Dynavax Technologies shares jumped more than 38% Wednesday after Sanofi announced a $15.50-per-share acquisition offer, valuing the company at roughly $2.2 billion.

French pharmaceutical giant Sanofi has announced plans to acquire U.S.-based biotech company Dynavax Technologies in a deal ...

Sanofi will pay $2.2 billion for Dynavax Techologies as it looks to add another Hepatitis B and new shingles vaccines to its portfolio.

Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.